A PHASE I STUDY OF B43 GENISTEIN IMMUNOCONJUGATE IN RECURRENT B-CELL LEUKEMIA

B43 金雀花素免疫缀合物治疗复发性 B 细胞白血病的 I 期研究

• 批准号: 6274920
• 负责人: ALEXANDRA M LEVINE
• 金额: $ 3.67万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274920
• 关键词: B cell lymphoma; clinical research; clinical trial phase I; drug adverse effect; drug screening /evaluation; genistein; human subject; human therapy evaluation; immunoconjugates; immunotherapy; neoplasm /cancer relapse /recurrence; nutrition related tag; pharmacokinetics

B-cell leukemia and lymphoma are malignancies which are responsive to chemotherapy. However, relapse of disease is common and thus new drugs are needed in the treatment of these malignancies. The purpose of the study is to define the side effects of b43-genistein immunoconjugate in humans and to determine the maximum tolerated dose when given as a daily 1 hour infusion for 10 days.

B 细胞白血病和淋巴瘤是对以下因素有反应的恶性肿瘤： 化疗。然而，疾病复发很常见，因此需要新药 治疗这些恶性肿瘤所需要的。研究的目的是 确定 b43-金雀异黄素免疫缀合物对人类的副作用 确定每日 1 小时给药时的最大耐受剂量 输液10天。